KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma

Navya Murugesan, Mayinuer Maitituoheti

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences